Clinical efficacy of short contact topical @entity1487 in the treatment of XXXX : a retrospective analysis.

@entity1 @entity7390 @entity1487
OBJECTIVE: To determine the efficacy of treating @entity1 with a recent onset, biopsy-proven keratoacanthoma with short-contact topical 5% @entity1487 cream twice daily until resolution. DESIGN: Chart review of 10 @entity1 who applied 5% @entity1487 for the treatment of biopsy-proven keratoacanthoma. SETTING: Outpatient clinic of a board-certified dermatologist. @entity1 : The study population was 90-percent @entity1 (9/10), 10-percent @entity1 (1/10) and ranged in ages from 52 to 92 years old with a mean age of 74.4. MEASUREMENTS: @entity1 were followed for weekly visits for the duration of their treatment and at varying, less-frequent intervals after resolution of the lesion clinically. Photographs were taken at each visit. RESULTS: The authors performed a retrospective analysis of 10 @entity1 with biopsy-confirmed @entity7390 treated with topical @entity1487 . One @entity1 elected to have Mohs surgery after one week of topical @entity1487 due to personal concern and cosmetic appearance and did not complain of any side effects due to the drug. Of the nine @entity1 that remained on topical @entity1487 , all @entity1 had complete resolution of the lesion within six weeks. The range in the number of weeks to resolution was four to six weeks. Two @entity1 required a one- to two-week drug holiday secondary to erythema, which resolved without any further complication or @entity1 discomfort. All nine @entity1 who continued therapy reported satisfaction with the results and showed excellent compliance with treatment. CONCLUSION: Short-contact topical 5% @entity1487 appears to provide excellent cosmetic results and is well-tolerated by @entity1 . This should be an initial consideration for the treatment of @entity7390 and does not preclude future surgical intervention if deemed necessary.
